● Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Condition: Multiple Myeloma in Relapse · Refractory Multiple Myeloma · Plasmacytoid; Lymphoma · Sponsor: iCell Gene Therapeutics

PhasePhase 1

Planned participants12

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Kevin Pinz, MS · 6315386218 · kevin.pinz@icellgene.com

Always discuss trial participation with your own doctor first.

Locations (2)

Peking University Shenzhen Hospital, China	Shenzhen, Guangdong, China	Recruiting
Chengdu Military General Hospital	Chengdu, Sichuan, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04162353